Evidence map›Paper›PMID 29289977›Full record

ArticleCancer immunology, immunotherapy : CII2018

Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.

Helen M McGuire, Elena Shklovskaya, Jarem Edwards, Paul R Trevillian, Geoffrey W McCaughan, Patrick Bertolino, Catriona McKenzie, Ralph Gourlay, Stuart J Gallagher, Barbara Fazekas de St Groth and 1 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  12. Review
  13. Hepatobiliary complications of immune checkpoint inhibitors in cancer.Exploration of targeted anti-tumor therapy · 2024
    Review
  14. Article
  15. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  16. Review
  17. Review
  18. Immunotherapy-induced Hepatotoxicity: A Review.Journal of clinical and translational hepatology · 2022
    Review
  19. Review
  20. Downregulated cytotoxic CD8Cellular & molecular immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Helen M McGuireMelanoma Immunology and Oncology Unit, Centenary Institute, University of Sydney, Sydney, Australia.
Elena ShklovskayaMelanoma Immunology and Oncology Unit, Centenary Institute, University of Sydney, Sydney, Australia.
Jarem EdwardsMelanoma Institute Australia, University of Sydney, Crows Nest, Australia.
Paul R TrevillianNewcastle Transplant Unit, John Hunter Hospital, New Lambton Heights, Australia.
Geoffrey W McCaughanLiver Immunology Program, Centenary Institute and AW Morrow Gastroenterology and Liver Centre, Sydney, Australia.
Patrick BertolinoLiver Immunology Program, Centenary Institute and AW Morrow Gastroenterology and Liver Centre, Sydney, Australia.
Catriona McKenzieTissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, Australia.
Ralph GourlayFaculty of Health and Medicine, School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.
Stuart J GallagherMelanoma Immunology and Oncology Unit, Centenary Institute, University of Sydney, Sydney, Australia.
Barbara Fazekas de St GrothRamaciotti Facility for Human Systems Biology, Charles Perkins Centre, University of Sydney, Sydney, Australia.
Peter HerseyMelanoma Immunology and Oncology Unit, Centenary Institute, University of Sydney, Sydney, Australia. peter.hersey@sydney.edu.au.
University of Sydney · AUCentenary Institute · AUJohn Hunter Hospital · AUMelanoma Institute Australia · AURoyal Prince Alfred Hospital · AUUniversity of Newcastle Australia · AU

Funding

National Health and Medical Research Council 1093017National Health and Medical Research Council GNT1037298
6 · The paper itself

Abstract

Effective treatment or prevention of immune side effects associated with checkpoint inhibitor therapy of cancer is an important goal in this new era of immunotherapy. Hepatitis due to immunotherapy with antibodies against PD-1 is uncommon and generally of low severity. We present an unusually severe case arising in a melanoma patient after more than 6 months uncomplicated treatment with anti-PD-1 in an adjuvant setting. The hepatitis rapidly developed resistance to high-dose steroids, requiring anti-thymocyte globulin (ATG) to achieve control. Mass cytometry allowed comprehensive phenotyping of circulating lymphocytes and revealed that CD4

Indexed as

Drug Resistance, NeoplasmAdrenal Cortex HormonesAgedAntibodies, MonoclonalCase-Control StudiesFemaleHepatitisHumansImmunotherapyMaleMelanomaMiddle AgedPrognosisProgrammed Cell Death 1 ReceptorT-LymphocytesAdrenal Cortex HormonesAntibodies, MonoclonalPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAnti-PD-1 therapyCorticosteroidsHepatitisImmune-related adverse eventsMelanomaT cell

Identifiers

PMID29289977
PMCPMC5860100
OpenAlexW2778761730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.